138 related articles for article (PubMed ID: 38688412)
1. Uterine adenosarcoma: Clinical significance of histological classification and SNP array analysis.
Ngo C; Cotteret S; Deneche I; Kfoury M; Chehab R; Tran-Dien A; Vibert J; Leary A; Gouy S; Maulard A; Morice P; Scoazec JY; Pautier P; Genestie C
Hum Pathol; 2024 Apr; 148():14-22. PubMed ID: 38688412
[TBL] [Abstract][Full Text] [Related]
2. High-grade Müllerian Adenosarcoma: Genomic and Clinicopathologic Characterization of a Distinct Neoplasm With Prevalent TP53 Pathway Alterations and Aggressive Behavior.
Hodgson A; Amemiya Y; Seth A; Djordjevic B; Parra-Herran C
Am J Surg Pathol; 2017 Nov; 41(11):1513-1522. PubMed ID: 28834809
[TBL] [Abstract][Full Text] [Related]
3. Mullerian adenosarcoma: clinicopathologic and molecular characterization highlighting recurrent BAP1 loss and distinctive features of high-grade tumors.
Momeni Boroujeni A; Kertowidjojo E; Wu X; Soslow RA; Chiang S; Da Silva EM; Weigelt B; Chui MH
Mod Pathol; 2022 Nov; 35(11):1684-1694. PubMed ID: 36138078
[TBL] [Abstract][Full Text] [Related]
4. Cluster of uterine mullerian adenosarcoma in the Washington, DC metropolitan area with high incidence of sarcomatous overgrowth.
Seidman JD; Wasserman CS; Aye LM; MacKoul PJ; O'Leary TJ
Am J Surg Pathol; 1999 Jul; 23(7):809-14. PubMed ID: 10403304
[TBL] [Abstract][Full Text] [Related]
5. Mullerian adenosarcoma: a clinicopathologic and immunohistochemical study of 55 cases challenging the existence of adenofibroma.
Gallardo A; Prat J
Am J Surg Pathol; 2009 Feb; 33(2):278-88. PubMed ID: 18941402
[TBL] [Abstract][Full Text] [Related]
6. Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup.
Lee JC; Lu TP; Changou CA; Liang CW; Huang HN; Lauria A; Huang HY; Lin CY; Chiang YC; Davidson B; Lin MC; Kuo KT
Mod Pathol; 2016 Sep; 29(9):1070-82. PubMed ID: 27255164
[TBL] [Abstract][Full Text] [Related]
7. Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.
Friedlander ML; Covens A; Glasspool RM; Hilpert F; Kristensen G; Kwon S; Selle F; Small W; Witteveen E; Russell P
Int J Gynecol Cancer; 2014 Nov; 24(9 Suppl 3):S78-82. PubMed ID: 25341585
[TBL] [Abstract][Full Text] [Related]
8. Adenosarcoma of the uterus: a clinicopathologic, DNA flow cytometric, p53 and mdm-2 analysis of 11 cases.
Blom R; Guerrieri C
Int J Gynecol Cancer; 1999 Jan; 9(1):37-43. PubMed ID: 11240741
[TBL] [Abstract][Full Text] [Related]
9. Microsatellite Instability Status and the Expression of p16 and Cyclin D1 Proteins in Uterine Adenosarcoma and Their Clinicopathological Significance.
Atilgan AO; Akcay EY; Ozen O; Haberal Reyhan AN; Ayhan A
Turk Patoloji Derg; 2023; 39(1):31-41. PubMed ID: 35876683
[TBL] [Abstract][Full Text] [Related]
10. Uterine Adenosarcoma: a Review.
Nathenson MJ; Ravi V; Fleming N; Wang WL; Conley A
Curr Oncol Rep; 2016 Nov; 18(11):68. PubMed ID: 27718181
[TBL] [Abstract][Full Text] [Related]
11. Uterine Adenosarcoma.
Ulrich UA; Denschlag D
Oncol Res Treat; 2018; 41(11):693-696. PubMed ID: 30326467
[TBL] [Abstract][Full Text] [Related]
12. Mesodermal (müllerian) adenosarcoma of the ovary: a clinicopathologic analysis of 40 cases and a review of the literature.
Eichhorn JH; Young RH; Clement PB; Scully RE
Am J Surg Pathol; 2002 Oct; 26(10):1243-58. PubMed ID: 12360039
[TBL] [Abstract][Full Text] [Related]
13. [Prognosis-related clinicopathologic characteristics of FIGO stage Ⅰ Müllerian adenosarcoma of uterus].
Wang Y; Liu AJ; Chen X; Song X
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):334-338. PubMed ID: 29783798
[No Abstract] [Full Text] [Related]
14. Primary extra-uterine and extra-ovarian mullerian adenosarcoma: case report and literature review.
Mandato VD; Torricelli F; Mastrofilippo V; Valli R; Aguzzoli L; La Sala GB
BMC Cancer; 2018 Feb; 18(1):134. PubMed ID: 29402239
[TBL] [Abstract][Full Text] [Related]
15. Mullerian adenosarcoma of the female genital tract.
McCluggage WG
Adv Anat Pathol; 2010 Mar; 17(2):122-9. PubMed ID: 20179434
[TBL] [Abstract][Full Text] [Related]
16. Mullerian adenosarcomas: an immunophenotypic analysis of 35 cases.
Soslow RA; Ali A; Oliva E
Am J Surg Pathol; 2008 Jul; 32(7):1013-21. PubMed ID: 18469708
[TBL] [Abstract][Full Text] [Related]
17. DICER1 mutations are frequent in müllerian adenosarcomas and are independent of rhabdomyosarcomatous differentiation.
Bean GR; Anderson J; Sangoi AR; Krings G; Garg K
Mod Pathol; 2019 Feb; 32(2):280-289. PubMed ID: 30266945
[TBL] [Abstract][Full Text] [Related]
18. Mixed Endometrioid Adenocarcinoma and Müllerian Adenosarcoma of the Uterus and Ovary: Clinicopathologic Characterization With Emphasis on its Distinction From Carcinosarcoma.
El Hallani S; Arora R; Lin DI; Måsbäc A; Mateoiu C; McCluggage WG; Nucci MR; Otis CN; Parkash V; Parra-Herran C; Longacre TA
Am J Surg Pathol; 2021 Mar; 45(3):374-383. PubMed ID: 33565764
[TBL] [Abstract][Full Text] [Related]
19. The Overexpression of Programmed Death-Ligand 2 in Uterine Adenosarcoma: Correlation with High-Grade Morphology, Mutant Type TP53 Expression and Clinical Outcomes.
Ok Atılgan A; Yılmaz Akçay E; Özen Ö; Haberal Reyhan AN; Ayhan A
Int J Surg Pathol; 2023 Jun; 31(4):352-364. PubMed ID: 35466759
[TBL] [Abstract][Full Text] [Related]
20.
Koyama M; Yamaguchi K; Chigusa Y; Yamanoi K; Taki M; Sunada M; Horie A; Hamanishi J; Minamiguchi S; Mandai M
Int Cancer Conf J; 2023 Apr; 12(2):120-125. PubMed ID: 36896195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
